Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has received a consensus rating of “Buy” from the sixteen research firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have given a hold rating and ten have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $21.50.

Several research analysts have recently commented on ALDR shares. Zacks Investment Research downgraded Alder Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 22nd. Cantor Fitzgerald reissued a “hold” rating and issued a $21.00 target price on shares of Alder Biopharmaceuticals in a report on Tuesday, October 23rd. ValuEngine raised Alder Biopharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, October 26th. BidaskClub raised Alder Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, November 3rd. Finally, Cowen set a $23.00 target price on Alder Biopharmaceuticals and gave the stock a “buy” rating in a report on Monday, November 5th.

Shares of ALDR traded up $0.34 on Friday, hitting $14.32. The company’s stock had a trading volume of 497,420 shares, compared to its average volume of 1,151,734. The company has a market capitalization of $978.44 million, a P/E ratio of -2.89 and a beta of 2.87. The company has a debt-to-equity ratio of 0.97, a current ratio of 15.34 and a quick ratio of 15.34. Alder Biopharmaceuticals has a fifty-two week low of $9.44 and a fifty-two week high of $20.87.

In other Alder Biopharmaceuticals news, insider Jeffrey T. L. Smith sold 5,044 shares of the company’s stock in a transaction on Monday, December 3rd. The stock was sold at an average price of $13.84, for a total transaction of $69,808.96. Following the transaction, the insider now owns 5,875 shares of the company’s stock, valued at approximately $81,310. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 17.40% of the stock is currently owned by corporate insiders.

A number of large investors have recently bought and sold shares of ALDR. TIAA CREF Investment Management LLC raised its position in shares of Alder Biopharmaceuticals by 748.3% during the 3rd quarter. TIAA CREF Investment Management LLC now owns 1,049,133 shares of the biopharmaceutical company’s stock valued at $17,468,000 after acquiring an additional 925,463 shares during the last quarter. Samlyn Capital LLC raised its position in shares of Alder Biopharmaceuticals by 47.2% during the 4th quarter. Samlyn Capital LLC now owns 2,818,788 shares of the biopharmaceutical company’s stock valued at $28,892,000 after acquiring an additional 904,098 shares during the last quarter. BB Biotech AG raised its position in shares of Alder Biopharmaceuticals by 22.1% during the 4th quarter. BB Biotech AG now owns 2,766,008 shares of the biopharmaceutical company’s stock valued at $28,352,000 after acquiring an additional 500,000 shares during the last quarter. Man Group plc raised its position in shares of Alder Biopharmaceuticals by 233.7% during the 3rd quarter. Man Group plc now owns 513,491 shares of the biopharmaceutical company’s stock valued at $8,550,000 after acquiring an additional 359,602 shares during the last quarter. Finally, Millennium Management LLC raised its position in shares of Alder Biopharmaceuticals by 168.5% during the 4th quarter. Millennium Management LLC now owns 477,310 shares of the biopharmaceutical company’s stock valued at $4,892,000 after acquiring an additional 299,538 shares during the last quarter.

About Alder Biopharmaceuticals

Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland.

Featured Article: Short Selling Stocks, A Beginner’s Guide

Analyst Recommendations for Alder Biopharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.